ClinicalTrials.gg
RecruitingNCT07127510ALZNADUpdated Mar 24, 2026

Brain NAD in Alzheimer's Disease

An observational study in Alzheimer Disease (AD), sponsored by Florida Atlantic University. Recruiting at 1 site in United States. Open to participants aged 65 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by Florida Atlantic University · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
20
Ages
65 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,941 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 444 under way, 40 of them phase 3. Alzheimer Disease · United States.

Planned enrollment
273rd of 309
20 · median 160
Started
2026
with 91 others
Observational
310 of 1,941
86 open now
Primary completion
2027-04
later than 161 of 443 live
Registered
1,832nd of 1,941
by date

Among the 1,941 studies in Alzheimer Disease with a site in United States, this one is the 273rd largest by planned enrollment of the 309 observational ones that give a count, is one of 92 that started in 2026, is one of 310 observational ones, reaches primary completion later than 161 of the 443 other live ones, and was the 1,832nd registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,941 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 65 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,941 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

The goal of this observational study is to learn about the levels of nicotinamide adenine dinucleotide (NAD) in the brains of people with Alzheimer's disease. The study aims to determine if brain NAD levels are lower in people with Alzheimer's disease compared with people of the same age group who do not have Alzheimer's disease.

Participants with or without Alzheimer's disease will have a brain imaging session where NAD will be measured using magnetic resonance spectroscopy (MRS). Eight months later, they will have a second, similar, brain imaging session.

03

Conditions studied

  • Alzheimer Disease (AD)

Browse trials for

Keywords

  • NAD
  • Alzheimer Disease (AD)
04

Who can participate

Ages eligible
65 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Primary care clinic, community.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants are able to come to the Florida Atlantic University Clinical Research Unit, are verbal and ambulatory.
  • Age 65 to 80 included.
  • People with Alzheimer's disease (AD): AD diagnosis established by the person's physician according to the following criteria: clinical diagnosis AND either positive amyloid PET-scan or FDA-approved positive CSF or blood test.

Exclusion criteria

Exclusion Criteria:

  • Under the age of 65 or over the age of 80.
  • Advanced dementia such that the person would require sedation for undergoing an MRI scan.
  • Receiving anti-amyloid intravenous treatments Leqembi or Kinsula.
  • Having an MRI-incompatible pacemaker or other MRI-incompatible hardware (e.g. comprising a metallic part).
  • Having a history of seizures.
  • Working at night.
  • Having cancer or having been diagnosed with cancer within the last 5 years (excluding superficial squameous or basal cell cancer).
  • People with no AD: test result lower than 26.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
20 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Alzheimer's disease group

    People diagnosed with Alzheimer's disease

  • Control group

    People without Alzheimer's disease

06

What researchers measure

Primary outcomes

  1. Brain NAD

    NAD levels measured by 1H-MRS

    Time frame: At enrollment and 8 months after enrollment

07

Study locations

1 of 1 sites recruiting
  • FAU Clinical Research Unit
    Boca Raton, Florida 33431, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Primary outcome measure data will be shared.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: IPD and supporting information will be available from June 2027 to Mai 2028.

Access criteria: The type of analyzes qualifying for data sharing will be those submitted for publication. After publication these data will be freely available. Before publication, a proposal describing planned analyses must be submitted to FAU Office of Research Integrity via the contact information available on the website, and a data sharing agreement must be signed between FAU and the receiving party.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Apr 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2025
First posted
Aug 17, 2025
StartActual
Mar 18, 2026
Primary completionEst.
Apr 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07127510
Lead sponsor
Florida Atlantic University
Responsible party
Corinne Lasmezas (Professor, Florida Atlantic University) — Principal investigator
First posted
Aug 17, 2025
Start date
Mar 18, 2026
Primary completion
Apr 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Mar 24, 2026

Study contacts

FAU Clinical Research Unit Central Contact
Contact
CRUDOR@health.fau.edu
561-235-4467
Corinne Lasmezas, PhD
principal investigator · Florida Atlantic University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion